U.S. regulators on Friday approved AbbVie’s new multidrug regimen for hepatitis C, and the company priced it below rival treatments from Gilead Sciences.
WSJ.com: Health, Wall Street Journal: Business: Health
Fri, 12/19/2014 - 6:47pm
U.S. regulators on Friday approved AbbVie’s new multidrug regimen for hepatitis C, and the company priced it below rival treatments from Gilead Sciences.